Levemir Innolet is a drug owned by Novo Nordisk Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2019. Details of Levemir Innolet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5750497 | Acylated insulin |
Jun, 2019
(5 years ago) |
Expired
|
| US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(7 years ago) |
Expired
|
| US6011007 | Acylated insulin |
Feb, 2014
(10 years ago) |
Expired
|
| US6869930 | Acylated insulin |
Feb, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Levemir Innolet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Levemir Innolet's family patents as well as insights into ongoing legal events on those patents.
Levemir Innolet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Levemir Innolet's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 16, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Levemir Innolet Generics:
There are no approved generic versions for Levemir Innolet as of now.
Alternative Brands for Levemir Innolet
Levemir Innolet which is used for managing blood sugar levels in patients with diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Detemir Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
| |||||||||
About Levemir Innolet
Levemir Innolet is a drug owned by Novo Nordisk Inc. It is used for managing blood sugar levels in patients with diabetes mellitus. Levemir Innolet uses Insulin Detemir Recombinant as an active ingredient. Levemir Innolet was launched by Novo Nordisk Inc in 2013.
Approval Date:
Levemir Innolet was approved by FDA for market use on 31 October, 2013.
Active Ingredient:
Levemir Innolet uses Insulin Detemir Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Detemir Recombinant ingredient
Treatment:
Levemir Innolet is used for managing blood sugar levels in patients with diabetes mellitus.
Dosage:
Levemir Innolet is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300 UNITS/3ML (100 UNITS/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |